Endocrinology, Diabetes and Metabolism最新文献

{"title":"Hyperglycaemia and Its Risk Factors Among Adults Living With HIV on Follow-Up at the Hawassa City Administration, Southern Ethiopia: A Cross-Sectional Study","authors":"Agete Tadewos Hirigo,&nbsp;Daniel Yilma,&nbsp;Ayalew Astatkie,&nbsp;Zelalem Debebe","doi":"10.1002/edm2.70054","DOIUrl":"https://doi.org/10.1002/edm2.70054","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ethiopia implemented the universal test and treat in 2017 and later adopted dolutegravir-based regimens for people living with HIV (PLWH). However, the impact of these changes on glucose metabolism in Ethiopia remains unclear, highlighting the need for further investigation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional study was conducted in southern Ethiopia from 5 January 2023 to 30 May 2024. We included 443 adult PLWH using systematic random sampling. American Diabetes Association criteria was used to define hyperglycaemia. To identify factors associated with hyperglycaemia, binary logistic regression was used with adjusted odds ratio (AOR) and 95% confidence interval (CI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall prevalence of hyperglycaemia was 24.4% (16.7% prediabetes and 7.7% diabetes mellitus [DM]). Of the participants with DM, 82.3% were newly diagnosed. Significant predictors of hyperglycaemia were age &gt; 50 years (AOR 2.1; 95% CI 1.1–3.9), alcohol intake (AOR 2.1; 95% CI 1.02–4.2), obesity (AOR 3.2; 95% CI 1.3–7.9), high waist–hip ratio (AOR 2.6; 95% CI 1.4–5.05) and LDL-cholesterol (AOR 2.2; 95% CI 1.02–4.6). While significant predictors of DM were alcohol intake (AOR 3.0; 95% CI 1.1–8.4), co-morbidity (AOR 2.6; 95% CI 1.1–6.05), high waist circumference (AOR 7.5; 95% CI 1.3–43.3), high waist–hip ratio (AOR 4.1; 95% CI 1.02–16.2) and high triglycerides (AOR 3.2; 95% CI 1.3–7.7). Dolutegravir-based regimen was not associated with hyperglycaemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Hyperglycaemia prevalence among adult PLWH on antiretroviral therapy in southern Ethiopia is rising, with most diabetes cases newly identified. This emphasises the critical need for routine screening to enable early detection, prevention and management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of GLP-1 Receptor Agonists on Paediatric Population in a Real World Setting","authors":"A. G. Barajas,&nbsp;Charles A. Gagnon-Vargas,&nbsp;Jessica A. Schmitt","doi":"10.1002/edm2.70053","DOIUrl":"https://doi.org/10.1002/edm2.70053","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Incidence of type 2 diabetes mellitus (T2DM) and obesity is increasing in children. We aimed to observe the metabolic health effects of glucagon-like peptide 1 (GLP-1) receptor agonists in paediatric patients with T2DM in a real-world setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective chart review of patients aged 0 to 18 years with T2DM who were started on a GLP-1 receptor agonist between August 2019 and August 2023 and followed for up to 24 months was included in this study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>321 patients were included in the analysis. After 12 months of treatment with a GLP-1 receptor agonist, haemoglobin A1c (HbA1c) was reduced by −1.04% ± 2.3% (<i>p</i> &lt; 0.001). At 24 months, HbA1c was similar to baseline (8.3% ± 2.5% vs. 7.9% ± 2.5%, <i>p</i> = 0.24). There was a significant (<i>p</i> &lt; 0.05) decrease in the use of metformin, basal insulin, and bolus insulin at one year which was sustained at the two-year follow-up for metformin (<i>p</i> = 0.002). Overall, there was no significant change in BMI nor other metabolic parameters while undergoing treatment with a GLP-1 receptor agonist.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Paediatric patients with T2DM using GLP-1 receptor agonists experienced a significant decrease in HbA1c after 12 months of use, which was not sustained at 24 months. However, patients had a reduction in insulin and metformin use at 12 months. No significant impact was appreciated on BMI or other metabolic variables.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70053","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Metformin Therapy on Vitamin B12 Levels in Patients With Type 2 Diabetes Mellitus","authors":"Sahar H. Mahmoud,&nbsp;Fatma R. Elfargani,&nbsp;Nagwa Mohamed,&nbsp;Fiaza A. Alhamdi","doi":"10.1002/edm2.70049","DOIUrl":"https://doi.org/10.1002/edm2.70049","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Diabetes mellitus (DM) is a serious health condition affecting people worldwide with a high prevalence rate. DM is classified according to its aetiology into type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM); several risk factors contribute to the development of T2DM, such as age, genetic predisposition and obesity. Metformin is a proven drug of choice, and it is used as a first-line treatment for patients with T2DM to improve their glycaemic levels. Vitamin B12 is an important water-soluble vitamin, and its deficiency can lead to megaloblastic anaemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>A Cross-sectional retrospective study was conducted on patients with T2DM in a Sedi Hussein diabetic polyclinic in Benghazi, Libya. The total sample was 381 patients: T1DM 15 (n), and T2DM 366 (n). T1DM was excluded from our results. Patients with T2DM were divided into two groups: the control group (not on metformin) consisted of 71 patients, and the group that received metformin (M group) consisted of 295 patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims of the Study</h3>\u0000 \u0000 <p>To assess serum vitamin B12 levels in patients with T2DM and evaluate the prevalence of vitamin B12 deficiency among those receiving metformin treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The M group significantly decreased vitamin B12 serum levels by 443.56 mg/mL versus the control group of 541.33 pg/mL (<i>p</i> = 0.003). The prevalence of patients with vitamin B12 deficiency under the metformin treatment was 23.84%. There was no significant difference in correlation between serum vitamin B12 levels and both doses of metformin and the duration of diabetes mellitus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Vitamin B12 was significantly decreased in patients with T2DM receiving metformin.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70049","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Performance of Two Systems for Automated Insulin Delivery in Adults With Type 1 Diabetes: An Observational Study","authors":"Sanne Fisker,&nbsp;Mia Christensen,&nbsp;Ermina Bach,&nbsp;Bo Martin Bibby,&nbsp;Klavs Würgler Hansen","doi":"10.1002/edm2.70043","DOIUrl":"https://doi.org/10.1002/edm2.70043","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To compare glycaemic outcomes for two automated insulin delivery (AID) systems, the Tandem Control IQ (CIQ) and the MiniMed 780G (MM780G).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>In this observational study, we evaluated 60 days of glycaemic data from 139 persons with type 1 diabetes (CIQ: 79 persons, MM780G: 60 persons), who had an active glucose sensor time ≥ 85%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The time with AID was median 620 (IQR, 439–755) days for CIQ users and 509 (429–744) days for MM780G users (<i>p</i> = 0.26). The last HbA1c before initiation of AID was 59.7 mmol/mol in CIQ and 60.1 mmol/mol in MM780G (<i>p</i> = 0.88). The time with an active glucose sensor was higher for CIQ than MM780G (median 98.5 (97.4–98.0)% vs. 96.5 (94.9–97.0)%, <i>p</i> &lt; 0.001). Time in range (TIR, glucose 3.9–10.0 mmol/L) was lower in CIQ than MM780G (mean 68.9% ± 11.4% vs. 73.7% ± 12.0%, <i>p</i> = 0.02) as was time in tight range (TITR) (glucose 3.9–7.8 mmol/L) (43.0% ± 12.2% vs. 48.4% ± 12.7%, <i>p</i> = 0.01). The difference in TIR (4.2 (95% CI 1.0–7.5)%, <i>p</i> = 0.01) and TITR (5.0 (1.4–8.6)%, <i>p</i> &lt; 0.01) remained statistically significant in a multiple regression model controlling for various baseline variables. Time with an absolute rate of glucose change &gt; 1.5 mmol/L/15 min was higher in CIQ than MM780G (9.4 (IQR, 7.2–13.3)% vs. 7.4 (5.2–10.4)%, <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The CIQ system had a higher active glucose sensor time but a lower TIR, TITR, and a higher time with a rapid glucose rate of change than the MM780G system.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143801473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight Gain, Weight Loss, and Type 2 Diabetes Risk: Evidence From the Atherosclerosis Risk in Communities (ARIC) Study","authors":"Samaneh Asgari,&nbsp;Soroush Masrouri,&nbsp;Davood Khalili,&nbsp;Mojtaba Lotfaliany,&nbsp;Farzad Hadaegh","doi":"10.1002/edm2.70040","DOIUrl":"https://doi.org/10.1002/edm2.70040","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>While type 2 diabetes (T2DM) has become a major health issue in the North American and Caribbean region, the effects of weight change on incident T2DM, conditional on either initial or attained weight, are poorly addressed. Therefore, we aimed to assess the impact of 3-year weight change on incident T2DM over 6 years among US individuals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 8377 participants aged 45–64 years (4601 women), free of T2DM or cancer at baseline from the Atherosclerosis Risk in Communities (ARIC) study were included. Weight measurements were taken at baseline (visit 1, 1987–89) and approximately 3 years later (visit 2, 1990–92). Participants were categorised based on their weight change ratio into ≥ 5% weight loss, stable (±5%), and ≥ 5% weight gain. Cox proportional hazards models, adjusting for known diabetes risk factors, were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of incident T2DM, with stable weight (±5%) as the reference category.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During a median follow-up period of 6 years, participants were classified into three categories: 361 persons remained stable (±5%), 47 with ≥ 5% loss, and 135 with ≥ 5% gain.</p>\u0000 \u0000 <p>In multivariable analysis, after adjustment with initial weight, ≥ 5% weight gain and loss were significantly associated with higher [HR (95% CI): 1.68 (1.36–2.06), <i>p</i>-value &lt; 0.0001] and lower [0.73 (0.53–1.00), <i>p</i>-value = 0.05] risks of incident T2DM, respectively. When adjusted for attained weight, weight gain ≥ 5% remained a significant risk factor for T2DM [1.51 (1.21–1.88)]; however, weight loss ≥ 5% lost statistical significance [0.84 (0.60–1.17), <i>p</i>-value = 0.31].</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We found a robust association between weight gain and incident T2DM; however, the beneficial impact of weight loss was significantly attenuated after considering the attained weight.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70040","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143801414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Once-Weekly Insulin Versus Once-Daily Insulin for Type 1 Diabetes Treatment: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","authors":"Obieda Altobaishat,&nbsp;Ahmed Farid Gadelmawla,&nbsp;Suliman Almohtasib,&nbsp;Husam Abu Suilik,&nbsp;AlMothana Manasrah,&nbsp;Mohamed Abouzid,&nbsp;Mustafa Turkmani,&nbsp;Mohamed Abuelazm","doi":"10.1002/edm2.70048","DOIUrl":"https://doi.org/10.1002/edm2.70048","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Type 1 diabetes mellitus (T1DM) represents a considerable global health burden, affecting approximately 5%–10% of individuals with diabetes. Once-weekly basal insulin could substantially reduce the number of injections for T1DM patients from 365 daily to 52 weekly doses annually. Therefore, this meta-analysis compares the safety and efficacy of once-weekly insulin formulations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The systematic review and meta-analysis included the relevant randomised controlled trials (RCTs) retrieved from PubMed, EMBASE, Web of Science, Cochrane, and SCOPUS databases until September 2024. The meta-analysis was performed using (RevMan 5.4.1). The study protocol was registered on PROSPERO (CRD42024603022).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three RCTs comprising 1724 participants were included. Once-daily insulin significantly decreased glycated haemoglobin (HbA1c) compared to once-weekly insulin (estimated treatment difference: 0.09%, 95% CI [0.07, 0.11], <i>p</i> &lt; 0.00001). Fasting blood glucose levels were comparable between the once-weekly and once-daily insulin groups (estimated treatment difference: 0.44 mg/dL, 95% CI [−0.64, 1.52], <i>p</i> = 0.42).</p>\u0000 \u0000 <p>Once-weekly insulin was associated with a significant increase in the incidence of injection site reactions (RR: 3.48 with 95% CI [1.30, 9.31], <i>p</i> = 0.01), serious adverse events (RR: 1.55 with 95% CI [1.09, 2.19], <i>p</i> = 0.01), and treatment-emergent adverse events (RR: 1.12 with 95% CI [1.02, 1.23], <i>p</i> = 0.02), while no significant difference was observed in hypersensitivity reactions (RR: 1.04 with 95% CI [0.78, 1.38], <i>p</i> = 0.79).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Once-daily insulin has demonstrated slightly superior HbA1c reduction, while once-weekly insulin offers potential advantages in patient adherence. However, these benefits must be weighed against an increased risk of injection site reactions and nocturnal hypoglycemia. Although once-weekly insulin is more convenient, treatment decisions should consider individual patient factors such as hypoglycemia risk and tolerance to injection reactions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70048","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143778415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies","authors":"Jimmy Wen,&nbsp;Burhaan Syed,&nbsp;Denise Nadora,&nbsp;Christiane How-Volkman,&nbsp;Ethan Bernstein,&nbsp;Alina Truong,&nbsp;Muzammil Akhtar,&nbsp;Adam Razick,&nbsp;Jose Puglisi,&nbsp;Eldo Frezza","doi":"10.1002/edm2.70045","DOIUrl":"https://doi.org/10.1002/edm2.70045","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as an efficacious treatment for type 2 diabetes mellitus (T2DM) and have demonstrated substantial weight loss effects. This systematic review compares two prevalent GLP-1RAs, tirzepatide and semaglutide, with their weight loss effects and rates of adverse events (AEs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a systematic search was performed in PubMed, Embase and Cochrane Library for direct comparative studies between tirzepatide and semaglutide. A meta-analysis was conducted via a random-effects model to analyse the differences in weight loss outcomes between study cohorts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Four studies, with 28,827 patients (14,870 tirzepatide/13,928 semaglutide), mean age of 55.7 years (52.0 to 63.7) and mean follow-up of 35.9 weeks (23.6 to 44.6), were included in this study. Mean weight change across four studies for tirzepatide and semaglutide was −11.4% (−15.3% to −8.27%) and −7.3% (−8.3% to −6.08%), respectively. The meta-analysis supports these findings with a mean difference of −4.84 kg (95% CI: −6.21 to −3.47), favouring tirzepatide. The most common AEs were minor and moderate-severity gastrointestinal (GI) AEs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Current literature supports tirzepatide demonstrating a higher impact on weight loss than semaglutide, with both demonstrating high rates of minimal- to moderate-severity AEs. Further research with comparative head-to-head trials will better elucidate these weight loss effects and safety profiles.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70045","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143778416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-Specific Impact of Metabolic Dysfunction-Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality","authors":"Mahsa Abbaszadeh,&nbsp;Farhad Hosseinpanah,&nbsp;Maryam Tohidi,&nbsp;Sahar Karimpour Reyhan,&nbsp;Maryam Mahdavi,&nbsp;Majid Valizadeh","doi":"10.1002/edm2.70035","DOIUrl":"https://doi.org/10.1002/edm2.70035","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Considering recent revisions in the nomenclature for fatty liver disease, alongside limited data on sex-specific differences in its cardiovascular/mortality outcomes, this study aims to investigate the prevalence and impact of metabolic-associated fatty liver disease (MAFLD) on cardiovascular disease (CVD) and mortality in men and women over a 12-year follow-up period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this large population-based cohort study, 7101 individuals aged ≥ 30 were enrolled. The prevalence of MAFLD was investigated in both genders. After excluding individuals with a history of previous CVD, 6331 participants were followed up for CVD and mortality over 12 years. Steatosis was defined as fatty liver index (FLI) ≥ 60. Multivariate-adjusted hazard ratios (HRs) were calculated for CVD and mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The prevalence of MAFLD was 43.2%, higher in men (46.5%) than women (40.6%). Men with MAFLD (47.7 ± 12.1) were younger than women (52.2 ± 11.1). In the 12-year follow-up of 6331 individuals, multivariable-adjusted CVD HRs for MAFLD were 1.36 (1.10–1.67) in men and 1.48 (1.16–1.88) in women. Adjusted mortality HRs were 1.17 (0.86–1.59) and 1.38 (1.00–1.91) in men and women, respectively. Among patients with MAFLD, a subgroup with diabetes faced the highest hazard for CVD and mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study found that MAFLD is more common in men at a younger age. Despite the higher prevalence in men, women with MAFLD face a greater risk of cardiovascular events and mortality. Findings highlight the importance of gender-specific considerations in primary prevention programmes for MAFLD-related cardiovascular disease and mortality.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship Between Irritable Bowel Syndrome and Metabolic Syndrome: A Systematic Review and Meta-Analysis of 49,662 Individuals","authors":"Yomna E. Dean,&nbsp;Jose J. Loayza Pintado,&nbsp;Samah S. Rouzan,&nbsp;Lucy L. Nale,&nbsp;Ahmed Abbas,&nbsp;Abdulla Aboushaira,&nbsp;Farah Alkasajy,&nbsp;Ahmed A. Ghanem,&nbsp;Vinayak Mahesh Patil,&nbsp;Yana Gordeyeva,&nbsp;Karam R. Motawea,&nbsp;Masako Lien Petty Le,&nbsp;Adham Galal,&nbsp;Laura Cicani,&nbsp;Raneem Attta,&nbsp;Ahmed Soliman,&nbsp;Lamya Alzabidi,&nbsp;Anuj Subedi,&nbsp;Nikhat Anjum,&nbsp;Abdullah Nahedh,&nbsp;Tamer Mady,&nbsp;Yusef Hazimeh,&nbsp;Hossam Amin,&nbsp;Hani Aiash","doi":"10.1002/edm2.70041","DOIUrl":"https://doi.org/10.1002/edm2.70041","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Studies have shown mixed results regarding the association between irritable bowel syndrome (IBS) and metabolic syndrome (MS); This study aimed to assess the susceptibility of IBS patients to MS and its individual components.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed, Scopus, Embase, and Web of Science were searched on 1/1/2023. Eligible studies were screened, and data on study characteristics, IBS diagnostic criteria, and metabolic syndrome components were extracted. Data were analysed in RevMan 5.4, with results reported as relative risk (RR) or mean difference (MD) and 95% confidence intervals. Statistical significance was set at <i>p</i> &lt; 0.05.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>IBS was associated with an increased risk of MS (RR = 2.05, 95% CI = 1.50–2.79, <i>p</i> &lt; 0.00001), with a higher risk among IBS-D patients (RR = 3.09, 95% CI = 2.41–3.97, <i>p</i> &lt; 0.00001). IBS patients showed increased HOMA-IR (MD = 0.21, 95% CI = 0.15–0.26, <i>p</i> &lt; 0.00001), higher obesity risk (RR = 1.46, 95% CI = 1.10–1.93, <i>p</i> = 0.009), elevated BMI (MD = 1.51, 95% CI = 0.98–2.03, <i>p</i>-value &lt; 0.00001), waist circumference (MD = 5.01, 95% CI = 1.29–8.72, <i>p</i> = 0.008), and an association with systolic hypertension (MD = −0.50, 95% CI = −0.60 to −0.40, <i>p</i>-value &lt; 0.00001). IBS was also linked to higher LDL (MD = 5.98, 95% CI = 0.91–11.05, <i>p</i> = 0.02), total cholesterol (MD = 12.21, 95% CI = 6.23–18.18, <i>p</i> &lt; 0.0001), and triglycerides (MD = 11.93, 95% CI = 11.55–12.31, <i>p</i> &lt; 0.00001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This analysis indicates a potential association between IBS and metabolic syndrome, including its components such as obesity, hypertension, and lipid profile abnormalities. However, significant heterogeneity among studies limits the generalisability of these findings. Clinicians should remain aware of the possible link and consider individualised preventive and management strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70041","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Nutrition Education on Glycemic Outcomes in People With Type 1 Diabetes Initiating the Use of Glucose Sensors","authors":"Vendula Navrátilová,&nbsp;Eliška Zadáková,&nbsp;Jan Šoupal,&nbsp;Jan Škrha Jr.,&nbsp;Quoc Dat Do,&nbsp;Lucie Radovnická,&nbsp;Aneta Hásková,&nbsp;Martin Prázný,&nbsp;Eva Horová","doi":"10.1002/edm2.70047","DOIUrl":"https://doi.org/10.1002/edm2.70047","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To determine whether people with type 1 diabetes (T1D) initiating glucose sensor monitoring experience greater improvements in HbA1c when provided with education on carbohydrate counting and flexible insulin dosing than those who do not receive nutrition education.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Our retrospective observational study included 329 people with T1D initiating glucose sensor monitoring between 2015 and 2021. The participants were divided into two groups: one group attended at least one structured educational session with a registered dietitian (<i>n</i> = 126), while the other group did not receive structured education (<i>n</i> = 203). After 12 months of glucose sensor initiation, we compared glycaemic outcomes and CGM metrics between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At glucose sensor initiation, both groups with and without education had similar HbA1c levels (7.64% [60.0 mmol/mol] vs. 7.66% [60.2 mmol/mol]). After twelve months, the education group demonstrated greater improvement in glycemic outcomes (HbA1c 7.17% [54.9mmol/mol] vs. 7.37% [57.1 mmol/mol], <i>p</i> &lt; 0.05) and spent significantly more time in the target range than did the group without structured education (68.8% vs. 64.1%, <i>p</i> &lt; 0.05). We observed an inverse correlation between the number of completed educational sessions and HbA1c after 12 months, as well as between the number of educational sessions and the change in HbA1c.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>People with T1D who initiated glucose sensor monitoring alongside nutrition education showed greater improvements in HbA1c and increased time spent in the target glucose range compared to individuals who did not receive structured education.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trail Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT06264271</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70047","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}